A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases : A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine
Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Nutrients - 9(2017), 5 vom: 15. Mai |
Sprache: |
Englisch |
---|
Links: |
---|
Anmerkungen: |
Date Completed 26.03.2018 Date Revised 02.12.2018 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/nu9050499 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM271899506 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM271899506 | ||
003 | DE-627 | ||
005 | 20231224233723.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/nu9050499 |2 doi | |
028 | 5 | 2 | |a pubmed24n0906.xml |
035 | |a (DE-627)NLM271899506 | ||
035 | |a (NLM)28505128 | ||
035 | |a (PII)E499 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Andersen, Vibeke |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases |b A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.03.2018 | ||
500 | |a Date Revised 02.12.2018 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Chronic inflammatory diseases (CIDs), including Crohn's disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a biomarker | |
650 | 4 | |a exercise | |
650 | 4 | |a food | |
650 | 4 | |a molecular epidemiology | |
650 | 4 | |a patient related outcome measures (PROMs) | |
650 | 4 | |a personalized medicine | |
650 | 4 | |a red meat | |
650 | 4 | |a smoking | |
650 | 4 | |a treatment outcome | |
650 | 4 | |a western style diet (WSD) | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a Dietary Fats |2 NLM | |
650 | 7 | |a Dietary Fiber |2 NLM | |
650 | 7 | |a Dietary Proteins |2 NLM | |
650 | 7 | |a Fatty Acids, Unsaturated |2 NLM | |
650 | 7 | |a Micronutrients |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
700 | 1 | |a Holmskov, Uffe |e verfasserin |4 aut | |
700 | 1 | |a Sørensen, Signe Bek |e verfasserin |4 aut | |
700 | 1 | |a Jawhara, Mohamad |e verfasserin |4 aut | |
700 | 1 | |a Andersen, Karina W |e verfasserin |4 aut | |
700 | 1 | |a Bygum, Anette |e verfasserin |4 aut | |
700 | 1 | |a Hvid, Lone |e verfasserin |4 aut | |
700 | 1 | |a Grauslund, Jakob |e verfasserin |4 aut | |
700 | 1 | |a Wied, Jimmi |e verfasserin |4 aut | |
700 | 1 | |a Glerup, Henning |e verfasserin |4 aut | |
700 | 1 | |a Fredberg, Ulrich |e verfasserin |4 aut | |
700 | 1 | |a Villadsen, Jan Alexander |e verfasserin |4 aut | |
700 | 1 | |a Kjær, Søren Geill |e verfasserin |4 aut | |
700 | 1 | |a Fallingborg, Jan |e verfasserin |4 aut | |
700 | 1 | |a Moghadd, Seyed A G R |e verfasserin |4 aut | |
700 | 1 | |a Knudsen, Torben |e verfasserin |4 aut | |
700 | 1 | |a Brodersen, Jacob |e verfasserin |4 aut | |
700 | 1 | |a Frøjk, Jesper |e verfasserin |4 aut | |
700 | 1 | |a Dahlerup, Jens F |e verfasserin |4 aut | |
700 | 1 | |a Nielsen, Ole Haagen |e verfasserin |4 aut | |
700 | 1 | |a Christensen, Robin |e verfasserin |4 aut | |
700 | 1 | |a Bojesen, Anders Bo |e verfasserin |4 aut | |
700 | 1 | |a Sorensen, Grith Lykke |e verfasserin |4 aut | |
700 | 1 | |a Thiel, Steffen |e verfasserin |4 aut | |
700 | 1 | |a Færgeman, Nils J |e verfasserin |4 aut | |
700 | 1 | |a Brandslund, Ivan |e verfasserin |4 aut | |
700 | 1 | |a Stensballe, Allan |e verfasserin |4 aut | |
700 | 1 | |a Schmidt, Erik Berg |e verfasserin |4 aut | |
700 | 1 | |a Franke, Andre |e verfasserin |4 aut | |
700 | 1 | |a Ellinghaus, David |e verfasserin |4 aut | |
700 | 1 | |a Rosenstiel, Philip |e verfasserin |4 aut | |
700 | 1 | |a Raes, Jeroen |e verfasserin |4 aut | |
700 | 1 | |a Heitmann, Berit |e verfasserin |4 aut | |
700 | 1 | |a Boye, Mette |e verfasserin |4 aut | |
700 | 1 | |a Nielsen, Charlotte Lindgaard |e verfasserin |4 aut | |
700 | 1 | |a Werner, Lars |e verfasserin |4 aut | |
700 | 1 | |a Kjeldsen, Jens |e verfasserin |4 aut | |
700 | 1 | |a Ellingsen, Torkell |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nutrients |d 2009 |g 9(2017), 5 vom: 15. Mai |w (DE-627)NLM206140738 |x 2072-6643 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2017 |g number:5 |g day:15 |g month:05 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/nu9050499 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2017 |e 5 |b 15 |c 05 |